Australia's most trusted
source of pharma news
Posted 12 February 2023 AM
Eight drugs recommended by the PBAC in 2023 have recently been marked as 'inactive,' signalling that sponsors are struggling to agree on the committee's conditions for PBS listing.
It follows a decision by Lilly to pull the launch of its first-in-class ulcerative colitis treatment Omvoh, after struggling to secure a feasible price from the government and prompting calls from the company for "substantial policy change".
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.